Risankizumab for treating moderately to severely active ulcerative colitis

Evaluation committee members

This topic was considered by the chair and vice chair of NICE's highly specialised technologies evaluation committee.

Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

Chair

Paul Arundel
Chair, highly specialised technologies evaluation committee

NICE project team

Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser and a project manager.

Alex Sampson
Technical lead

Zoe Charles
Technical adviser

Jeremy Powell
Project manager

ISBN: 978-1-4731-6210-5